icer white paper affordable access to glp-1 obesity medications 2025 Insurance coverage just changed for as many as 56 million Americans when it comes the popular used to promote weight loss. Story🔗below A KFF analysis shows that

Triple Receptor Mechanism Retatrutide is the first molecule to simultaneously engage all three receptors implicated in energy balance and body weight regulation: GLP-1 receptor: Reduces appetite, slows gastric emptying, improves glycemic control the same pathway as semaglutide (Ozempic/Wegovy) GIP receptor: Enhances insulin secretion and may contribute to fat mobilization the same dual pathway as tirzepatide (Mounjaro/Zepbound) Glucagon receptor: Increases energy expenditure, promotes hepatic fat oxidation, and drives thermogenesis a pathway unique to retatrutide among obesity therapeutics Clinical Significance In the Phase 2 trial published in the New England Journal of Medicine (2023), participants receiving the highest dose of retatrutide achieved a mean body weight reduction of 24.2% at 48 weeks with some participants losing over 30% of their body weight

Small-molecule ferroptotic agents with potential to selectively target cancer stem cells

This can translate into increased sensitivity to UV exposure and a potentially higher susceptibility to photoaging-related processes such as oxidative stress, collagen degradation, and DNA damage in skin cells

A powerful ingredient for advanced skin and hair rejuvenation formulas

doi: 10.1212/NXI.0000000000001102 287 ZhangQSunWWangQZhengXZhangRZhangN